about
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersLink between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatmentGenerating human intestinal tissues from pluripotent stem cells to study development and diseaseGlucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice.Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males.The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.Monomethylated-adenines potentiate glucose-induced insulin production and secretion via inhibition of phosphodiesterase activity in rat pancreatic islets.Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.Drugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRsPeripheral Pathways in the Food-Intake Control towards the Adipose-Intestinal Missing Link.The alpha-cell as target for type 2 diabetes therapy.Incretin hormones and beta-cell mass expansion: what we know and what is missing?Glucose metabolism in critically ill patients: are incretins an important player?The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Acute and short-term effects of caloric restriction on metabolic profile and brain activation in obese, postmenopausal women.The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1.Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.The structure of wheat bread influences the postprandial metabolic response in healthy men.Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?(Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.Why is it so difficult to measure glucagon-like peptide-1 in a mouse?Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries.Gut hormones of preterm infants with abdominal symptoms and hypothyroxinemia.Effects of small intestinal glucose on glycaemia, insulinaemia and incretin hormone release are load-dependent in obese subjects.Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet.Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies
P2860
Q26777654-8B2241B1-A6BD-4931-A2F6-78106927CB05Q26860246-5E84AC32-132B-4603-9587-D53EAA1344DAQ28081264-5EE70FA6-7CD9-420D-92E1-0CA8986C8E6AQ33800196-265D8311-E6AA-485F-ADBE-9AC6D6C8A0AFQ34990233-8FEB4061-97B5-4E22-AA41-379BEA8AC260Q34996877-C5D890F8-AEBC-4636-8608-E5C98EC03CD3Q35532329-7094CDD6-4D51-46F2-9F67-2F9451C90872Q35669476-4BB07B4C-5B87-4062-9187-ABA53A6BA700Q35760275-454F4F99-C3E0-4046-8921-89CD7868929EQ36930349-1CE5A1E1-5501-4BD9-B12B-D9BA57BA96A8Q36994382-D19D9778-941E-403D-AFB7-D6BC54AEC7D7Q37237145-32CDF6B8-FC7C-4943-888A-68B450B166AFQ37408131-5045FC6B-7633-4611-BD66-AE5F8401A21BQ37977335-ED2BADE7-2680-4DC3-9A4D-053138E69234Q38108631-B84ED522-C9E1-40FE-A2E7-F23ED19EEE5DQ38142955-2AD2A360-E726-4438-9EB8-B4681E87E83FQ38527885-0EBD1BDA-9B53-4801-AE4D-D95D48940B2DQ38783130-DFB749FB-07EE-45DD-8658-7E004C5E8302Q39047697-E72D090C-0958-4F36-BF9F-EC8DE26857DBQ39741865-2F3A844C-E95E-4A0F-8208-E47EF2FCBB28Q40036292-376F4B47-F4D2-4A0F-930B-1F9ACBCA3FC4Q40557047-AFD4ECB1-B6E1-4B71-A314-15547DB38F69Q40626757-4A947B7F-E6F6-4B36-AFDB-C9848B5C2F04Q42730475-FA695B41-C004-410B-8780-B56E41D0D2F3Q44476616-A3DDD578-D1A9-42A7-840B-8820415E3549Q46341700-D33422AB-28A6-4ABA-8458-1F7119DA0351Q47297477-3E6D3F6A-449A-414C-8C71-3CD89AB24B40Q48255700-E64036EC-4009-4E1D-92E7-86291F2ABA02Q51311269-24B6642A-57A8-4C52-8EDF-D1F45C73EA2AQ53553149-ED000998-24D4-4A63-9D43-AF466201A4CCQ55516133-1F3F0BD0-D7FE-46D9-8E60-138C8057CEF6Q58447614-D1938D3C-9ED2-4A19-A659-018E9B3A561B
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Physiology of incretins in health and disease.
@ast
Physiology of incretins in health and disease.
@en
type
label
Physiology of incretins in health and disease.
@ast
Physiology of incretins in health and disease.
@en
prefLabel
Physiology of incretins in health and disease.
@ast
Physiology of incretins in health and disease.
@en
P2860
P356
P1476
Physiology of incretins in health and disease.
@en
P2093
Carolyn F Deacon
P2860
P304
P356
10.1900/RDS.2011.8.293
P577
2011-11-10T00:00:00Z